Trial Profile
A prospective,multicenter,non-interventional study to evaluate the outcomes in patients with Psoriatic arthritis treated with ustekinumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms SUSTAIN
- 05 Jun 2021 Status changed from recruiting to completed, according to Results presented at the 22nd Annual Congress of the European League Against Rheumatism.
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism.
- 06 Jun 2020 Interim Results evaluating the data of 336 included patients till week 112 presented at the 21st Annual Congress of the European League Against Rheumatism